Maxwell Biotech Group currently has 9 biotech companies in its portfolio, which are engaged in the development of 11 innovative clinical stage drugs. 


Biotechnology company


29.09.2016 by in category News with 0 and 0
Home > News > News > Eleventa Announce Completion of Patient Enrollment in Phase 3 Clinical Trial of CRTH2 antagonist Timapiprant for the treatment of allergic asthma

Eleventa Announce Completion of Patient Enrollment in Phase 3 Clinical Trial of CRTH2 antagonist Timapiprant for the treatment of allergic asthma

Eleventa Ltd. (Moscow, Russia), a portfolio company of Maxwell Biotech Venture Fund (MBVF), and its development partner, Oxagen Limited (Abingdon, UK), today announced the completion of patient enrollment in the a Phase 3 clinical study of Timapiprant (formerly OC000459), for treatment of  atopic eosinophilic asthma in adults. Two hundred twelve patients have been enrolled in the randomized, double-blind study in 21 centers in Russia.

The main objective of the study is to assess the effect of Timapiprant on respiratory function, safety, tolerability and quality of life. The patients receive Timapiprant/placebo 50mg once daily over a treatment period of 12 weeks.

“Timapiprant is intended to reduce airway inflammation and improve control in patients with chronic eosinophilic airways disease, and so reduce dependence on inhaled corticosteroids. A positive trial outcome in Phase 3 trial will further highlight the potential of Timapiprant where new therapies are needed urgently”, said Tim Edwards, Executive Chairman, Oxagen Limited.

“Eleventa’s Timapiprant is effective single systemic therapy for asthma and co-morbid allergies. Its persistent anti-allergic effects and desensitisation may halt the disease progression and provide the improved asthma control in millions of patients”, said Dmitry Popov, Managing Partner of MBVF.

About Timapiprant (OC000459)

Timapiprant, once-a-day oral tablet, is a highly potent and selective antagonist to the CRTH2 receptor. The drug blocks the host response to allergen and reduces eosinophilic airway inflammation which plays a key role in the manifestation of chronic respiratory disease leading to exacerbations. Due to this specific mechanism, the drug is devoid of local and systemic side effects related to glucocorticoid therapy.

About Eleventa

Eleventa is a biotechnology company founded in 2012 to develop and commercialize innovative products for the treatment of asthma and other allergic and inflammatory respiratory diseases. Resident of Skolkovo Innovation Center.

About Maxwell Biotech Venture Fund

MBVF is the first Russian venture fund fully dedicated to investments in the Life Sciences technologies. The fund has been created with participation of RVC. MBVF portfolio companies have nine innovative clinical drug candidates in development.

Press contacts

Natalia Bakrenko, Maxwell Biotech Group, +7 (495) 726-52-53, bakrenko@ammaxwell.ru


© Eleventa, 2012—2020